Zymeworks Inc
ZYME16.490USD
+0.620+3.91%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
1.16BCap. mercado
PérdidaP/E TTM
Más Datos de Zymeworks Inc Compañía
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Información de la empresa
Símbolo de cotizaciónZYME
Nombre de la empresaZymeworks Inc
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoMr. Kenneth H. (Ken) Galbraith
Número de empleados280
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 24
Dirección108 Patriot Drive, Suite A
CiudadMIDDLETOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19709
Teléfono13022748744
Sitio Webhttps://www.zymeworks.com/
Símbolo de cotizaciónZYME
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoMr. Kenneth H. (Ken) Galbraith
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Neil Gallagher, M.D., Ph.D.
Dr. Neil Gallagher, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Otro
47.10%
Accionistas
Accionistas
Proporción
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Otro
47.10%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
50.52%
Investment Advisor
23.12%
Hedge Fund
18.92%
Research Firm
5.96%
Private Equity
1.70%
Individual Investor
0.81%
Venture Capital
0.45%
Pension Fund
0.30%
Sovereign Wealth Fund
0.27%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
2023Q1
340
64.28M
100.47%
-34.07M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
EcoR1 Capital, LLC
22.97M
30.69%
+5.09M
+28.44%
Jun 26, 2025
Rubric Capital Management LP
4.34M
5.8%
+421.11K
+10.75%
Mar 31, 2025
BVF Partners L.P.
4.31M
5.76%
--
--
Mar 31, 2025
Redmile Group, LLC
4.79M
6.4%
-51.52K
-1.06%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.30M
4.42%
-169.56K
-4.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
4.54%
-93.86K
-2.69%
Mar 31, 2025
The Vanguard Group, Inc.
1.76M
2.35%
-718.49K
-28.98%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
2.20M
2.94%
+222.17K
+11.25%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.38M
1.85%
+812.87K
+142.68%
Mar 31, 2025
UBS Asset Management (Americas) LLC
1.60M
2.14%
+1.60M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de sep
Actualizado: mar., 2 de sep
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
1.13%
Tema Oncology ETF
1.13%
iShares Micro-Cap ETF
0.14%
Federated Hermes MDT Small Cap Core ETF
0.13%
WisdomTree US SmallCap Quality Growth Fund
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
SPDR S&P International Small Cap ETF
0.06%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.13%
Tema Oncology ETF
Proporción1.13%
iShares Micro-Cap ETF
Proporción0.14%
Federated Hermes MDT Small Cap Core ETF
Proporción0.13%
WisdomTree US SmallCap Quality Growth Fund
Proporción0.1%
ProShares Ultra Nasdaq Biotechnology
Proporción0.1%
iShares Biotechnology ETF
Proporción0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.09%
SPDR S&P International Small Cap ETF
Proporción0.06%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
